Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282190 | 0.97 | AOC3 (0.32) | PTPN11DGAT1KCNH2PKMAOC3 | |
| SCHEMBL1283092 | 0.96 | PTPN11 (0.31) | PTPN11DGAT1KCNH2 | |
| SCHEMBL1282983 | 0.93 | PTPN11 (0.32) | PTPN11PKMAOC3ALDH1A1 | |
| SCHEMBL1282937 | 0.92 | PTPN11 (0.32) | PTPN11PKMAOC3 | |
| SCHEMBL1283728 | 0.91 | PTPN11 (0.31) | PTPN11PKMAOC3 | |
| SCHEMBL1283461 | 0.91 | MLYCD (0.34) | PTPN11KCNH2PKMAOC3 | |
| SCHEMBL1282501 | 0.91 | KCNH2 (0.42) | DGAT1KCNH2ALDH1A1 | |
| SCHEMBL1282552 | 0.91 | DGAT1 (0.32) | DGAT1KCNH2 | |
| SCHEMBL1283632 | 0.91 | PTPN11 (0.31) | PTPN11PKM | |
| SCHEMBL1282559 | 0.91 | PTPN11 (0.31) | PTPN11PKMAOC3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | claimed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | PTPN11 4067/4885DGAT1 2241/4885KCNH2 2727/4885 |
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | PTPN11 2315/4885DGAT1 596/4885KCNH2 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.